Human islet cell transplantation - Future prospects

Diabetic Medicine

Volumn 18, Issue 2, 2001, Pages 78-103

  White, S A ^a   James, R F L ^a   Swift, S M ^a   Kimber, R M ^a   Nicholson, M L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Diabetes mellitus; Islet; Islet of Langerhan; Islet transplant; Tolerance

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; AZATHIOPRINE; CAMPATH 3; CYCLOSPORIN A; FINGOLIMOD; GLYCOPROTEIN GP 39; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEFLUNOMIDE; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45; MONOCLONAL ANTIBODY RIB1/2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ALLOTRANSPLANTATION; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; GENETIC ENGINEERING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LANGERHANS CELL; NONHUMAN; ORGAN DONOR; ORGAN PRESERVATION; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PANCREAS RESECTION; REVIEW; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; CRYOPRESERVATION; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MEDLINE; REGISTRIES; TISSUE AND ORGAN HARVESTING; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035085242     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2001.00465.x     Document Type: Review

References (410)

1. Can islet cell transplantation treat diabetes?
2. Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid free immunosuppressive regimen
3. Islet xenotransplantation
4. Xenotransplantation
5. Human fetal pancreas transplants
6. Fetal islet xenotransplantation in rodents and primates
7. Human islet autotransplantation
8. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
9. Diabetic comas
10. Pancreas and islet transplantation
11. Mortality after vascularised pancreas transplantation
12. International pancreas transplant registry. Worldwide pancreas transplants
13. Decreased surgical risks of pancreas transplants in the modern era
14. Vascularised pancreas transplantation - Clinical indications and outcome
15. Percutaneous transhepatic catheterisation of the portal vein: A combined CT and fluoroscopy-guided technique
16. Weaning of immunosuppression in liver transplant recipients
17. International islet transplant registry
18. International islet transplant registry
19. Pancreatic transplantation (islet cell)
20. Treatment of isolated pancreatic islets to reverse pancreatectomy induced and insulin dependent Type 1 diabetes in humans: A 6 year experience
21. Islet transplantation in IDDM patients
22. Human islet transplantation: Lessons from 13 autologous and 13 allogeneic transplantations
23. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement
24. Human islet allografts in patients with Type 2 diabetes undergoing liver transplantation
25. One year follow-up of simultaneous islet-kidney SIK or islet after kidney (IAK) transplantation (Tx) in patients with type 1 diabetes mellitus
26. Improved survival of intraportal pancreatic islet allografts in patients with type 1 diabetes mellitus by refined peritransplant management
27. Stimulation of cell replication intransplanted pancreatic islets by nicotinamide treatment
28. Pentoxifilline partially reverts the effect of tumour necrosis factor on human islets
29. Improved glucose counterregulation and autonomic symptoms after intraportal islet transplant alone in patients with longstanding type 1 diabetes mellitus
30. Long-term (> 3 year) insulin independence in a patient with pancreatic islet cell transplantation following upper abdominal exenteration and liver replacement for fibrolamellar hepatocellular carcinoma
31. Transplantation of islets of Langerhans with insulin requiring diabetes mellitus undergoing orthotopic liver transplantation - The Miami experience
32. Human islet cotransplantation with liver or kidney
33. Simultaneous islet-liver transplantation: Preliminary results from the UC islet transplantation consortium
34. Islet mass and function in diabetes and transplantation
35. Morphometrical analysis on topographical difference in size distribution, number and Volume of islets in the human pancreas
36. Distal pancreatectomy in chronic pancreatitis
37. Pancreatectomy for chronic pancreatitis
38. Simultaneous pancreas-kidney transplantation from live donors
39. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans
40. Critical islet mass in islet autotransplantation after pancreas resection
41. Preserved insulin secretion and insulin independence in recipients of islet autografts
42. Metabolic effects of successful intraportal islet transplantation in insulin dependent diabetes mellitus
43. Long-term function (6 years) after islet allografts in Type 1 diabetes
44. Insulin secretory patterns and blood glucose homeostasis after islet allotransplantation in IDDM patients: A comparison with segmental or whole pancreas transplanted patients through a long-term longitudinal study
45. Successful islet auotransplantation in humans. Functional insulin secretory reserve as an estimate of surviving islet cell mass
46. Pancreas resection and islet autotransplantation for end-stage chronic pancreatitis
47. Continued function of pancreatic islets after transplantation in type I diabetes
48. Insulin prophylaxis in individuals at high risk of type 1 diabetes
49. Effect of intensive therapy on residual beta cell function in patients with Type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group
50. Brain death and its influence on donor organ quality and outcome after transplantation
51. The endocrine pancreas in brain dead donors. A prospective study in 25 patients
52. Effects of explosive brain death on cytokine activation of peripheral organs in rat
53. Accelerated rejection of renal allografts from brain dead donors
54. Non-heartbeating organ donors: A potential source of islets for transplantation
55. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors
56. Donor hyperglycemia as a minor risk factor and immunologic variables as major risk factors for pancreas allograft loss in a multivariate analysis of a single institution's experience
57. Variables in organ donors that affect the recovery of human islets of Langerhans
58. Influence of donor data and organ procurement on human islet isolation
59. Donor factors impacting human islet yield and their in vivo function
60. Donor factors effecting successful isolation of islets from the human pancreas
61. Analysis of donor age and cold ischaemia as factors in cadaveric human islet isolation
62. Human islet isolation in 104 consecutive cases
63. Correlation between donor characteristics and human pancreatic islet yield and purity
64. Human pancreas preservation prior to islet isolation - Cold ischaemic tolerance
65. The effect of multiple-organ donation on the degree of preservation of isolated pancreas islets
66. Influence of human donor operation and isolation techniques on the viability of islets of Langerhans
67. The evaluation of solutions for pancreas preservation prior to islet isolation
68. Islet isolation from human pancreas stored in UW solution for 6-26 hours
69. Human islet isolation - A prospective randomised comparison of pancreatic vascular perfusion with hyperosmolar citrate or University of Wisconsin solution
70. Results, research priorities, and reasons for optimism: Islet transplantation for patients with Type 1 diabetes
71. Critical components of storage fluid for pancreas preservation before islet isolation
72. Human islet isolation after prolonged cold storage
73. A simple method for the release of islets by controlled collagenase digestion of the human pancreas
74. Activation of pancreatic proteolytic enzymes by commercial collagenases
75. Function of pancreatic autografts following 24 hours cold storage with HTK solution
76. Successful extended preservation of ischaemically damaged pancreas by the two-layer (University of Wisconsin/perfluorochemical) cold storage method
77. Excellence of the two-layered method (University of Wisconsin solution perflurochemical) in pancreas preservation before islet isolation
78. Distant processing of pancreas islets for autotransplantation following total pancreatectomy
79. Endotoxin contamination may be responsible for the unexplained failure of human pancreatic islet transplantation
80. Endotoxin impairs the engraftment of rat islets transplanted beneath the kidney capsule of C57bl/6 mice
81. Endotoxin mediated activation of cytokine production in human PBMCs by collagenase and Ficoll
82. Endotoxin contaminating islet preparations may explain primary non-function of human islet grafts
83. Isolated human pancreatic islets in vitro activate human complement
84. Nitric oxide mediates islet dysfunction of rat and mouse islets after transplantation
85. Collagenase and human islet isolation
86. A complementary substrate specificities of class I and class II collagenases from Clostridium histolyticum
87. Histochemical analysis of the role of class I and class II clostridium collagenasein the degradation of rat pancreatic extracellular matrix for islet isolation
88. Sterile filtration of collagenase solution: Effect of filter membrane composition on enzyme recovery
89. A preliminary study of the activation of endogenous pancreatic enzymes during automated porcine islet isolation
90. Prophylactic trypsin inhibition during the isolation procedure guarantees reproducible, high porcine islet yields
91. Factors influencing the isolation process of islets of Langerhans
92. Effect of prophylactic administration of trypsin inhibitors in porcine pancreas isolation
93. Active pancreatic digestive enzymes show striking differences in their potential to damage isolated rat pancreatic acinar cells
94. pH elevation in collagenase digestion medium increases islet yields obtained from human pancreas
95. An analysis of the role of collagenase and protease in the enzymatic dissociation of the rat pancreas for islet isolation
96. The influence of different loading pressures on the distribution of collagenase within the porcine pancreas
97. Peri-insular presence of collagenase during islet isolation procedures
98. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion
99. Influence of different collagenase solvents and timing of their delivery on porcine islet isolation
100. Improvement in islet yield from a cold-preserved pancreas by pancreatic ductal collagenase distention at the time of harvesting
101. Cold-storage preservation of the canine and rat pancreas prior to islet isolation
102. Comparison of human islet isolation in fresh or after preservation in two different protocols using UW solution
103. Early intraductal injection of liberase does not improve the result of human islet isolation. The results of a randomized controlled trial
104. Storage of pancreatic digest before islet purification. The influence of colloids and the sodium to potassium ratio in University of Wisconsin based preservation solutions
105. Impact of cold ischemia and timing of intraductal collagenase distension on human islet yield, purity, viability and survival in low temperature culture
106. Safety testing of Liberase®, a purified enzyme blend for human islet isolation
107. Improved human islet isolation using a new enzyme blend, Liberase®
108. Recombinant enzymes for islet isolation: Purification of a collagenase from Clostridium histolyticum and cloning/expression of the gene
109. Automated method for isolation of human pancreatic islets
110. Pancreatic islet transplantation. Is purification necessary?
111. Monitoring of insulin content during human islet isolation
112. Disseminated intravascular coagulation and portal hypertension following pancreatic islet autotransplantation
113. Autologous islet transplantation to prevent diabetes after pancreatic resection
114. Hepatic infarction following intraportal islet celt autotransplantation after near-total pancreatectomy
115. Portal hypertension, hepatic infarction and liver failure complicating pancreatic islet autotransplantation
116. Fatal disseminated intravascular coagulation after autologous islet transplantation
117. Splenic infraction after autologous human islet infusion
118. Portal venous thrombosis after transplantation of partially purified pancreatic islets in a combined human liver islet allograft
119. Exocrine contamination impairs implantation of pancreatic islets transplanted beneath the kidney capsule
120. Comparison of splenic and renal subcapsular islet autografting in dogs
121. Does the purity of intraportal islet isografts affect their endocrine function?
122. Transplantation of purified single-donor canine islet allografts with cyclosporine
123. A comparison of canine renal and islet transplantation with cyclosporine: Assessment of islet immunogenicity
124. Transplantation of purified islet cells in diabetic rats. II. Immunogenicity of allografted islet beta-cells
125. Evidence for direct and indirect pathways in the generation of the alloimmune response against pancreatic islets
126. Disruption of epithelial cell matrix interactions induces apoptosis
127. Long-term in vivo function of human mantled islets obtained by incomplete pancreatic dissociation and purification
128. Anoikis, extracellular matrix and apoptosis factors in isolated cell transplantation
129. Intercellular communication and maintenance of islet cell mass - Implications for islet transplantation
130. The insulin-pancreatic acinar axis
131. Ductal cyst formation in collagen embedded adult human islet preparation
132. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator
133. Approaches to islet purification
134. Pancreatic islet isolation with UW solution: A new concept
135. Storage of human pancreatic digest in University of Wisconsin solution significantly improves subsequent islet purification
136. The effectiveness of components of University of Wisconsin solution in improving human pancreatic islet purification
137. Storage of porcine pancreatic digest prior to islet purification: The benefits of UW solution and the role of its individual components
138. The use of continuous density gradients for the assessment of islet and exocrine tissue densities and islet purification
139. The effect of osmolality and glucose concentration on the purity of human islet isolates
140. Method for the isolation of intact islets of Langerhans from the rat pancreas
141. The use of Ficoll in the preparation of viable islets of Langerhans from the rat pancreas
142. The use of a new dextran gradient medium for rapid isolation of functionally intact neonatal rat pancreatic islets
143. Bovine serum albumin density gradient isolation of rat pancreatic islets
144. Islet purification using EuroFicoll gradients
145. The evaluation of neutral density separation utilizing Ficoll-sodium diatrizoate and Nycodenz and centrifugal elutriation in the purification of bovine and canine islet preparations
146. Porcine and human islet purification: Evaluation of selected synthetic media
147. Iodixanol. A non-ionic isoosmotic centrifugation medium for the formation of self generated gradients
148. Satisfactory islet isolate number and viability with Iodixanol [Optiprep] discontinuous gradient centrifugation
149. Large scale isopycnic islet purification utilizing non-toxic, endotoxin free media facilitates immediate single-donor pig islet allograft function
150. New powerful tool for human islet purification optiprep-UWS
151. Selective photodynamic laser treatment of dispersed pancreatic tissue for islet isolation
152. Separation of pancreatic islets by fluorescence-activated sorting
153. Osmotic separation of pancreatic exocrine cells from crude islet cell preparations
154. Optimisation of the magnetic field used for immunomagnetic islet purification
155. Survival and function of islets during culture
156. Culture of normal human leukocytes
157. Prolongation of islet allograft survival following in vitro culture (24°C) and a single injection of ALS
158. Activation of intraislet lymphoid cells causes destruction of islet cells
159. Effect of low temperatures on glucose-induced insulin secretion and glucose metabolism in isolated pancreatic islets of the rat
160. In vitro function of adult pig islets: Effect of culture in different media
161. Effect of maintenance glucose concentration and length of culture on the glucose-induced insulin response of isolated rat islets
162. Impaired β cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose
163. Prolonged exposure of pancreatic islets isolated from 'pre-diabetic' non-obese diabetic mice to a high glucose concentration does not impair beta-cell function
164. Immunological and insulin secretory studies on isolated porcine islets of Langerhans
165. Functional studies of rat, porcine and human pancreatic islets cultured in ten commercially available media
166. Microbial contamination risks in human islet isolation
167. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans
168. Production of TNFalpha, IL-1, IL-6, and nitric oxide by isolated human islets
169. Methods for growth of cultured cells in serum free medium
170. Isolated mouse pancreatic islets in culture: Effects of serum and different culture media on the insulin production of the islets
171. Effects of glucose on the ultrastructure and insulin biosynthesis of isolated mouse pancreatic islets maintained in tissue culture
172. Effects of serum and medium supplements, pH, temperature on the viability of cultured porcine islets
173. Improved long term culture of functional human islets in serum free media
174. In vitro islet culture development of a serum free medium
175. A comparison of media supplement methods for the extended culture of human islet tissue
176. Normoglycaemia after transplantation of freshly isolated and cryopreserved pancreatic islets in type 1 (insulindependent) diabetes mellitus
177. Human islet transplantation: The Leicester experience
178. Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with type 1 (insulin-dependent) diabetes mellitus
179. The effect of cryopreservation on the survival and MHC antigen expression of murine islet allografts
180. Expression of HLA in isolated human pancreatic islets and cryopreservation
181. Pancreatic islet banking: The transplantation of frozen-thawed rat islets transported between centres
182. Reversal of diabetes in dogs by transplantation of pure cryopreserved islets
183. Subzero preservation of mechanically prepared porcine islets of Langerhans: Response to glucose challenge in-vitro
184. Cryogenic storage of isolated, purified porcine pancreatic islets
185. Islet cryopreservation
186. Methods of islet cryopreservation
187. Effects of pre-cryopreservation culture on human islet recovery and in vitro function
188. Survival of cryopreserved isolated adult human pancreatic islets of Langerhans
189. Islet cryopreservation: A detailed study of total functional losses
190. Prolonged cryopreservation of purified human pancreatic islets
191. Cryopreservation of rat pancreatic islets-effect of ethylene glycol on islet function and cellular composition
192. Osmotic responses of isolated canine islets to novel cryoprotectants
193. No correlation between in vitro and in vivo function of human islets
194. Perifusion of isolated rat islets in vitro: Participation of the microtubular system in the biphasic release of insulin
195. Evidence of in vivo human islet graft function despite a weak response to in vitro perifusion
196. Reversal of diabetes in nude mice after transplantation of fresh and 7-day-cultured (24°C) human pancreatic islets
197. Successful reversal of diabetes in nude rats by transplantation of isolated adult human islets of Langerhans
198. The diabetic 'human reconstituted' severe combined immunodeficient (SCID-hu) mouse: A model for isogeneic, allogeneic, and xenogeneic human islet transplantation
199. Studies on the diabetogenic actions of streptozotocin (NSC 37919)
200. Sensitivity of porcine islet beta cells to the diabetogenic action of streptozotocin
201. A microfluorometric viability assay for isolated human and rat islets of Langerhans
202. The use of fluorescein diacetate and ethidium bromide as a viability stain for isolated islets of Langerhans
203. Rapid assessment of islet cell viability by MTT assay after cold storage on different solutions
204. Optimisation of the conditions for the use of confocal laser scanning microscopy to study islet viability following culture in vitro
205. Three-dimensional distribution of damaged cells in cryopreserved pancreatic islets as determined by laser scanning confocal microscopy
206. Transplantation of isolated pancreatic islets into the portal vein of diabetic rats
207. Transplantation of pancreatic islets into the spleen of diabetic rats and subsequent splenectomy
208. Renal subcapsular islet cell transplantation
209. Homotransplantation of isolated pancreatic islets
210. Effect of tranplantation site on the results of pancreatic islet isografts in diabetic rats
211. Survival and function of purified islets in the omental pouch site of outbred dogs
212. Intrathymic islet transplantation in the spontaneously diabetic BB rat
213. Studies of privileged sites and islet transplantation
214. Intratesticular transplants of islet xenografts (rat to mice)
215. Epiploic flap: A new site for islet implantation in man
216. The rectum as a novel site for islet cell transplantation
217. Intrathecal allotransplantation of rat pancreatic islets by lumbar puncture
218. Improved islet survival and in vitro function using small intestinal submucosa
219. Tissue culture preservation and intramuscular transplantation of pancreatic islets
220. A comparison of the effects of a selective increase in peripheral insulin on hepatic glucose production
221. Detection of pancreatic islet tissue following islet allotransplantation in man
222. Immunocytochemical detection and chracterisation of intrahepatic human pancreatic islets after combined liver-islet allotransplantation
223. Intraportal human islet autotransplantation: An immunohistochemical study of islets in situ
224. Comparison of various sites of islet autotransplantation
225. The effect of transplantation site and islet mass on longterm survival and metabolic and hormonal function of canine purified islet autografts
226. Intraportal and intrasplenic autotransplantation of pancreatic islets in the dog
227. Autotransplantation of pancreatic fragments to the portal vein and spleen of totally pancreatectomized dogs: A comparative evaluation
228. Glucose metabolism, insulin sensitivity, and glucagon secretion in dogs with intraportal or intrasplenic islet autografts
229. Insulin deficiency and increased intact and 32/33 split proinsulin secretion following human islet autotransplantation
230. Biphasic release of insulin from islets of Langerhans after their transplantation into the liver of rats
231. Defective glucagon secretion during sustained hypoglycaemia following successful islet allo and auto transplantation in humans
232. The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycaemia is transplant site-determined
233. Pancreatic islet transplantation prevents defective glucose counter-regulation in diabetic dogs
234. Successful autotransplantation of isolated islets of Langerhans in the cynomolgus monkey
235. Metabolic function of intraportal and intrasplenic islet autografts in cynomolgus monkeys
236. The risks of total pancreatectomy and splenic islet autotransplantation
237. Regional cytokine changes following OKT3 induction for islet cell transplantation in humans: Early increase in portal and systemic levels of interleukin-6 and tumor necrosis factors
238. Effect of tumor necrosis factor alpha and of the soluble tumor necrosis factor receptor on insulin secretion of isolated islets of Langerhans
239. Role of nitric oxide in the pathogenesis of early pancreatic islet dysfunction during rat and human intraportal islet transplantation
240. Portal vein immunosuppressant levels and islet toxicity
241. Proliferation and hypertrophy of liver cells surrounding islet grafts in diabetic recipient rats
242. The renal subcapsular site offers better growth conditions for transplanted mouse pancreatic islet cells than the liver or spleen
243. Measurements of oxygen tension in native and transplanted rat pancreatic islets
244. Coencapsulation of allogeneic islets with allogeneic sertoli cells prolongs graft survival without systemic immunosuppression
245. Testicular sertoli cells exert both protective and destructive effects on syngeneic islet grafts in non-obese diabetic mice
246. Induction of donor-specific unresponsiveness by intrathymic islet transplantation
247. CT-guided fine needle approach for intrathymic islet transplantation in diabetic patients
248. Mechanisms of tolerance induction after intrathymic islet injection
249. Prevention of autoimmune diabetes in the BB rat by intrathymic islet transplantation at birth
250. Intrathymic islet cell transplantation reduces beta-cell autoimmunity and prevents diabetes in NOD/Lt mice
251. Prevention of overt diabetes and insulitis by intrathymic injection of syngeneic islets in new born non-obese diabetic (NOD) mice
252. Blood flow to the rabbit pancreas with special reference to the islets of Langerhans
253. The vascular order of islet cellular perfusion in the human pancreas
254. Cellular changes in cultures of mouse thyroid glands and islets of Langerhans
255. Intraportally transplanted pancreatic islets revascularised from hepatic arterial system
256. Histogenesis and ultrastructure of pancreatic islet graft microvasculature.Evidence for graft revascularisation by endothelial cells of host origin
257. Altered microcirculation and secretion in transplanted islets
258. Restitution of intra-islet portal system in pancreatic islet isografts
259. Pancreatic beta cells are rendered glucose competent by insulinotropic hormone glucagon like peptide
260. Vulnerability of islets in the immediate post-transplantation period.Dynamic chanegs in structure and function
261. Effect of hyperglycaemia and of one week culture of islets on the revasculariation of pancreatic islet isografts
262. Influence of persistent hyperglycemia on transplanted pancreatic islets
263. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients
264. The influence of prednisolone on revascularization of pancreatic islet grafts
265. Cyclosporine does not inhibit the process of revascularizarion of pancreatic islet transplantation
266. Induction of angiogenesis by growth factors: Relevance to pancreatic islet transplantation
267. Hepatocyte growth factor is essential for amelioration of hyperglycaemia in streptozotocin induced diabetic mice receiving a marginal mass of intrahepatic islet grafts
268. A morphological study of intrahepatic portal-vein isografts
269. Reinnervation of transplanted pancreatic islets: A comparison among islets implanted into the kidney, spleen, and liver
270. Neural control of insulin secretion
271. Reinnervation of intraportal islet allografts in rats
272. Cephalic phase insulin secretion in normal and pancreatic islettransplanted rats
273. Reinnervation of pancreatic islets and regulation of insulin secretion by hepatic sympathetic nerves after intraportal transplantation of islets into livers of diabetic rats
274. Human islet isolation and allotransplantation in 22 consecutive cases
275. Inhibitory effect of insulin upon C-peptide secretion in isolated human pancreatic islets
276. Development of diagnostic markers for islet allograft reiection
277. CD44 splice variants in draining lymph nodes precede allograft rejection of endocrine cells
278. Human islet preparations and the expression of MHC antigens
279. Immunobiology of tissue transplantation: A return to the passenger leucocyte concept
280. Indirect presentation of MHC antigens in transplantation
281. I1-2 knockout recipient mice reject islet cell allografts
282. Cytokine gene expression in pancreatic islet grafts in the rat
283. Species differences in human and rat islet sensitivity to human cytokines. Monoclonal anti-interleukin-1 (IL-1) influences on direct and indirect IL-1-mediated islet effects
284. Effect of cytokines on 'de novo' lipid synthesis and hormone secretion by isolated human islets
285. + T cell mediated rejection of pancreatic islet allografts
286. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT 3
287. Oxygen radical production in human mononuclear blood cells is not suppressed by drugs used in clinical islet transplantation
288. Cyclosporine and islet massimplications for islet transplantation
289. Failure of canine islet allografts and autografts with cyclosporine
290. Cyclosporin-induced inhibition of insulin secretion in isolated rat islets and HIT cells
291. Direct effects of cyclosporin A on human pancreatic beta-cells
292. FK 506 for liver, kidney, and pancreas transplantation
293. Transcriptional inhibition of insulin and possible involvement of FK 506 binding protein-12 in pancreatic beta cell
294. A comparison of tacrolimus (FK 506) and cyclosporin for immunosuppression after cadaveric renal transplantation
295. In vivo effect of FK506 on human pancreatic islets
296. Effects of FK 506 and cyclosporin on dynamic insulin secretion from isolated dog pancreatic islets
297. Diabetogenic effects of FK 506 on renal subcapsular islet isografts
298. Update of tacrolimus in pancreas transplantation
299. Azathioprine decreases insulin secretion in human islets
300. Toxicity of azathioprine and monocrotaline in murine siunsoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venoocclusive disease
301. Detrimental effect of prednisone on canine islet autograft function
302. Steroid diabetes in renal transplant recipients: Pathogenetic factors and prognosis
303. Insulin resistance and insulin deficiency in the pathogenesis of posttransplant diabetes in man
304. The in vivo and in vitro effect of 15-deoxyspergualin on pancreatic islet function
305. Effect of 15-deoxyspergualin (DSG) on immediate function and long-term survival of transplanted islets in recipients of a marginal islet mass
306. The effect of 15-deoxyspergualin on the endocrine function of the rat pancreas
307. Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin
308. Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15-deoxyspergulain but sensitive to anti-CD-4 antibody
309. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients
310. The use of rapamycin in organ transplantation
311. Sirolimus reduces the incidence of acute rejection episodes despite lowercyclosporine doses in Caucascian recipients of mismatched primary renal allografts: A phase II trial
312. Sirolimus-tacrolimus combination immunosuppression
313. Pharmacodynamic assessment of mycophenolate acid in a canine model
314. Effect of mycophenolate mofetil on islet allografting to chemically induced or spontaneously diabetic animals
315. In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function
316. Prolonged survival of islet allografts following combined therapy with Tacrolimus and Leflunomide
317. Effect of a new immunosuppressive agent, FTY720 on survival of islet allografts
318. Augmentation with bone marrow of donor leucocyte migration for kidney, liver, heart and pancreas islet transplantation
319. Donor dentritic cells re-population in recipients after rat to mouse bone marrow transplantation
320. Granulocyte/macrophage colony stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival
321. Higher percentage of donor CD 34+ expression in peripheral blood of simultaneous pancreas/kidney/donor bone marrow versus than kidney/islet cell/donor bone marrow recipients
322. High-dose bone marrow infusion to enhance allograft survival. The effect of timing
323. Lymphoid dendritic cells
324. Reduction in immunogenicity of human islets by 24°C culture
325. Long-term survival of rat islet allografts after pretreatment with low dose gamma irradiation
326. Interstitial class II-positive cell depletion by donor pretreatment with gamma irradiation. Evidence of differential immunogenicity between vascularized cardiac allografts and islets
327. Survival and function of human islets subjected to gamma radiation
328. Rat pancreatic islet pretreatment with anti MHC class II monoclonal antibodies and culture. In vitro MLIC test response does not predict islet allograft survival
329. Inability of UV irradiated lymphocytes to stimulate allogeneic cells in MLC
330. Induction of graft acceptance by UV irradiation of donor tissue
331. Ultraviolet-B irradiation for immunoalteration of human islets
332. Isolated human islet transplanted into diabetic nude mice after ultraviolet B irradiation
333. Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody
334. Pretreatment of rat pancreatic islets with MHC I-A monoclonal antibody: In-vitro and in-vivo effects on islet antigenicity
335. Modulation of MHC class I antigen decreases pancreatic islet immunogenicity
336. Prolongation of murine allograft survival by pretreatment of islets with antibody directed to Ia determinants
337. Prolongation of in vivo mouse islet allograft survival by modulation of MHC class I antigen
338. A new look at polyclonal anti-lymphocyte antibodies in clinical transplantation
339. Cytokine mRNA expression in peripheral blood cells of immunosuppressed human islet transplant recipients
340. Induction of antigen-specific unresponsiveness to pancreatic islet allografts by antilymphocyte serum
341. + T cells and inversion of the CD4/CD8 T cell ratio induced by anti-CD4 therapy
342. The kinetics of tolerance induction by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus intravenous donor alloantigen administration
343. Co-stimulation of T-lymphocytes the role of CD28, CTLA-4 and B.7/BBI in interleukin 2 production and immunotherapy
344. Survival of mouse pancreatic islet allogrfats in recipients treated
345. Immunosuppressive effects of human CTLA4Ig in nonhuman primate model of allogeneic pancreatic islet transplantation
346. Preventing effect of anti-ICAM-1 and anti-LFA-1 monoclonal antibodies on murine islet allograft rejection
347. A potential immunosuppressive effect of antilymphocyte function associatd antigen-1 monoclonal antibody on islet transplantation
348. Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-g or IL-4
349. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig
350. Inhibition of transplant rejection following treatment with anti-B7-2 and anti B7-1 antibodies
351. The role of donor and recipient B7-1 (CD80) in allograft rejection
352. Prolongation of rat islet allograft survival by treatment with monoclonal antibodies against VLA-4 and LFA-1
353. The role of CD28/B7 costimulatory pathway on recurrent autoimmunity after islet transplantation in autoimmune NOD mice
354. Indefinite islet allograft survival in mice after a short course of treatment with anti-CD45 monoclonal antibodies
355. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154
356. Prevention of T cell activation by rhCTLA-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival
357. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with co-stimulatory blockade is followed by central T cell tolerance
358. Phase 1 study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection
359. Campath1H allows low dose cyclopsorine monotherapy in 31 cadaveric renal allograft recipients
360. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with Basiliximab, a chimeric anti-leukin-2 receptor monoclonal antibody
361. Effect of temporary IL-2 receptor MAB therapy on islet allograft in autoimmune diabetes
362. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
363. Microencapsulated islets as bioartifcial endocrine pancreas
364. Optimisation of microencapsulation parameters: Semi-permeable microcapsules as a bioartificial pancreas
365. Transplantation of microencapsulated pancreatic human islets for therapy of diabetes mellitus. A preliminary report
366. Recent advances in alginate-based microcapsules
367. Islet microencapsulation: A review
368. An immunological basis for fibrotic reaction to implanted microcapusles
369. + helper T cells in the destruction of microencapsulated islet xenografts in nod mice
370. Prolonged functional survival of rat-to-NOD mouse islet xenografts by ultraviolet-B (UV-B) irradiation plus microencapsulation of donor islets
371. Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets
372. Alginate coating of islets of Langerhans: In vitro studies on a new method for encapsulation for immunoisolated transplantation
373. Production of mitogen contamination free alginates with variable ratios of mannuronic acid to guluronic acid by free flow electrophoresis
374. Insulin independence in a Type I diabetic patient after encapsulated islet transplantation
375. Prevention of Type 1 diabetes and recurrent B cell destruction of transplanted islets
376. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients
377. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody negative IDDM recipients of intrahepatic grafts
378. Evidence of recurrent autoimmunity in human allogeneic islet transplantation
379. Pancreas transplantation - An update
380. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts
381. Islet and pancreatic transplantationautoimmunity and alloimmunity
382. Destruction of xenogeneic (human) islet grafts triggered by NOD derived, insulin specific T cells in vivo
383. Prevention of autoimmune but not allogeneic destruction of grafted islets by different therapeutic strategies
384. Effect of cyclosporine on immunologically mediated diabetes in nonobese diabetic mice
385. Endothelial cells in pancreatic islets and the effect of culture
386. Fas ligand mediates activation-induced cell death in human T lymphocytes
387. Prevention of islet allograft rejection with engineered myoblasts expressing Fas L in mice
388. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts
389. Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection
390. Fas ligand transfected myoblasts and islet cell transplantation
391. B cell destruction in NOD mice correlates with Fas (CD95) expression on B cells and pro-inflammatory cytokine expression in islets
392. Modulating auto-immune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice
393. Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen pulsed syngeneic dendritic cells
394. Gene therapy for diabetes: Strategies for beta cell modification and replacement
395. Generation of nonimmune islet cells using genetic engineering
396. Desferrioxamine treatment prevents chronic islet allograft damage
397. Protection of mouse islet isografts from non-specific inflammatory damage by recipient treatment with nicotinamide and 15 deoxyspergualin
398. Beneficial effects of anti-oxidants in diabetes. Possible protection of pancreatic B cells against glucose toxicity
399. Leptin or Troglitazone induced lipopenia protects islets from intreleukin 1B cytotoxicity
400. Prevention of primary islet isograft nonfunction in mice with pravastatin
401. Beneficial effects of 1,25 Dihydroxyvitamin D3 on cytokine treated human pancreatic islets
402. Transplantation of allogeneic islets of Langerhans in the rat liver
403. Adenovirus mediated catalase gene transfer reduces oxidant stress in human, porcine and rat pancreatic islets
404. Complementary action of anti-oxidant enzymes in the protection of bioengineered insulin producing RINm5F cells against the toxicity of reactive oxygen species
405. Targeted over-expression of Cu/Zn superoxide dismutase protects pancreatic beta cells against oxidative stress
406. Inhibition of submandibular and lacrimal gland infiltartion in nonobese diabetic mice by transgenic expression of soluble TNF-receptor p55
407. Transfection of human pancreatic islets with an anti-apoptotic gene (bcl-2) protects B cells from cytokine induced destruction
408. Adenoviral gene transfer of the interleukin 1 receptor antagonist protein to human islets prevents IL-1β induced β cell impairment and activation of islet cell apoptosis in vitro
409. In vitro cultivation of human islets from expanded ductal tissue
410. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells